• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies.

作者信息

Puzo Christian J, Seropian Stuart, Rinder Henry, Tormey Christopher A, Siddon Alexa J

机构信息

Yale School of Medicine, New Haven, CT, USA.

Department of Hematology, Yale School of Medicine, New Haven, CT, USA.

出版信息

Bone Marrow Transplant. 2025 Apr;60(4):535-537. doi: 10.1038/s41409-025-02510-8. Epub 2025 Jan 13.

DOI:10.1038/s41409-025-02510-8
PMID:39806028
Abstract
摘要

相似文献

1
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies.确定用于治疗髓系恶性肿瘤的供体淋巴细胞输注的谱系特异性嵌合阈值。
Bone Marrow Transplant. 2025 Apr;60(4):535-537. doi: 10.1038/s41409-025-02510-8. Epub 2025 Jan 13.
2
Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis.通过高灵敏度嵌合分析指导晚期髓系恶性肿瘤的抢先性和治疗性供体淋巴细胞输注
Front Oncol. 2022 Aug 17;12:867356. doi: 10.3389/fonc.2022.867356. eCollection 2022.
3
Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.异基因造血干细胞移植后供受者谱系嵌合体监测与分析：移植前变量的影响及其与移植后结局的相关性。
Transplant Cell Ther. 2021 Sep;27(9):780.e1-780.e14. doi: 10.1016/j.jtct.2021.05.020. Epub 2021 May 31.
4
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.使用氟达拉滨和白消安联合方案进行减低强度干细胞移植后早期完全供体髓系嵌合现象
Haematologica. 2001 Oct;86(10):1071-4.
5
Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.基于传统和谱系特异性嵌合分析对清髓性异基因造血细胞移植后髓系恶性肿瘤患者进行免疫调节治疗的评估。
Leukemia. 2005 May;19(5):814-21. doi: 10.1038/sj.leu.2403719.
6
Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.慢性髓性白血病异基因骨髓移植后通过p210(BCR-ABL)和p190(BCR-ABL)的逆转录聚合酶链反应进行谱系特异性嵌合体和微小残留病的分子分析：混合髓系嵌合体增加和p190(BCR-ABL)检测先于细胞遗传学复发。
Blood. 2000 Apr 15;95(8):2659-65.
7
CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome.CD34 嵌合导向供者淋巴细胞输注联合或不联合阿扎胞苷在异基因造血干细胞移植后急性髓系白血病/骨髓增生异常综合征患者获得完全供者嵌合时可降低复发率并提高总生存率。
Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):e852-e860. doi: 10.1016/j.clml.2024.07.006. Epub 2024 Jul 20.
8
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.在基于阿仑单抗的异基因移植后，主要或完全的受者 T 细胞嵌合被供者淋巴细胞逆转，且与移植物衰竭无关。
Br J Haematol. 2012 Feb;156(4):516-22. doi: 10.1111/j.1365-2141.2011.08944.x. Epub 2011 Dec 15.
9
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.在血液系统恶性肿瘤异基因移植后复发和未复发的情况下，使用供者淋巴细胞输注治疗混合嵌合体和高危患者人群，如果持续获得或维持完全供者嵌合体，则与高五年生存率相关。
Biol Blood Marrow Transplant. 2017 Nov;23(11):1989-1997. doi: 10.1016/j.bbmt.2017.07.007. Epub 2017 Jul 13.
10
Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.急性髓系白血病异基因造血干细胞移植后与供者嵌合状态相关的早期完全嵌合与复发风险
Bone Marrow Transplant. 2022 May;57(5):753-759. doi: 10.1038/s41409-022-01615-8. Epub 2022 Feb 24.

本文引用的文献

1
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
2
Utility of assessing CD3 cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.异基因造血干细胞移植后最初几个月内评估 CD3 细胞嵌合体在急性髓系白血病中的应用。
HLA. 2022 Jul;100(1):18-23. doi: 10.1111/tan.14557. Epub 2022 Jan 30.
3
The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.
显而易见的问题：异基因造血细胞移植后急性髓系白血病复发
Front Oncol. 2022 Jan 3;11:793274. doi: 10.3389/fonc.2021.793274. eCollection 2021.
4
Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals.肿瘤医疗专业人员使用东部肿瘤协作组（ECOG）评分对癌症患者进行的体能状态评估。
Case Rep Oncol. 2019 Sep 25;12(3):728-736. doi: 10.1159/000503095. eCollection 2019 Sep-Dec.
5
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
6
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.异基因造血移植后的混合性T淋巴细胞嵌合现象可预测急性髓系白血病和骨髓增生异常综合征的复发。
Biol Blood Marrow Transplant. 2015 Nov;21(11):1948-54. doi: 10.1016/j.bbmt.2015.07.005. Epub 2015 Jul 14.
7
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.减低强度预处理造血干细胞移植后早期供体嵌合现象可预测复发和生存。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1516-21. doi: 10.1016/j.bbmt.2014.05.025. Epub 2014 Jun 4.
8
Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.采用半自动 CD34+供体细胞嵌合分析监测异基因造血干细胞移植后的急性髓系白血病患者。
Ann Hematol. 2014 Feb;93(2):279-85. doi: 10.1007/s00277-013-1961-4. Epub 2013 Dec 19.
9
Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.117例接受含白消安的减低强度预处理方案的异基因干细胞移植患者中T细胞嵌合状态对临床结局的影响。
Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-1155. doi: 10.1016/j.bbmt.2008.07.013.
10
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.急性髓系白血病治疗试验的诊断、反应标准标准化、治疗结果及报告标准国际工作组修订建议
J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.